Multiple Myeloma 2021 - Episode 12
Nina Shah, MD, discusses some of the important phase 3 trials to emerge from the previous year in multiple myeloma.
Nina Shah, MD: There are several ongoing phase 3 trials that I’m hopeful that we’ll see data from. Some of them would include the Perseus trial [NCT03710603], which looks at daratumumab-RVd [lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone] versus RVd with a true primary end point of PFS [progression-free survival]. There are also some Car T-cell [therapy] trials, which are randomizing patients to get Car T-cell therapy versus standard salvage therapy. I’m excited to see what happens there because one of the things we know about myeloma therapy is that using it in later lines might be great but using it in earlier lines almost always is better. Those are the major phase 3 trials I’m looking forward to. We’ve had some readout from randomized phase 2 trials, like the FORTE [NCT02203643] data, which have been very impressive. There are a lot of data coming out with isatuximab [Sarclisa] in the next few years that are going to help us to understand how to best position that drug as well.